Coenzyme Q10 (Ubiquinol) for Parkinson's Disease
Also known as: CoQ10, Ubiquinol, Ubiquinone
Mitochondrial Complex I dysfunction is a hallmark of Parkinson's, making CoQ10 a logical neuroprotective candidate.
Mechanism of Action
In Parkinson's, Complex I activity is reduced by 30-40% in the substantia nigra. CoQ10 supplementation aims to restore electron transport chain function, reduce oxidative stress in dopaminergic neurons, and support ATP production for neuronal survival.
General mechanism: Mitochondrial electron transport chain cofactor (Complex I/II → III). Lipid-soluble antioxidant. Regenerates vitamin E.
Current Evidence
The QE3 Phase III trial at 2400mg/day was stopped for futility — no benefit detected. However, the trial enrolled patients already on dopaminergic therapy, potentially masking neuroprotective effects. Earlier intervention studies show trends toward benefit.
Clinical Status: Phase III negative for Parkinson's. Available as supplement. Disease-modification studies inconclusive.
Safety Profile
Very safe. Mild GI effects. May interact with warfarin (vitamin K-like structure). Well-tolerated at high doses (2400mg+).
Key Research Questions
- Would earlier intervention (prodromal or newly diagnosed) yield different results?
- Can CoQ10 combination with LRRK2 inhibitors address both mitochondrial and kinase pathology?